Cancer drug cocktail shows promise for uterine tumors, but trial halted early

NCT ID NCT05481645

Terminated Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug combination for people with advanced endometrial cancer or uterine sarcoma who had not yet received treatment. The combination included an immunotherapy drug (TQB2450) plus chemotherapy, with or without a targeted therapy (anlotinib). The goal was to see if the drugs could shrink tumors. The trial was terminated early, so the full results are not available, but it aimed to find a better first-line option for these cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB2450 (a drug that helps the immune system fight cancer) combined with chemotherapy, with or without anlotinib (a drug that blocks tumor blood vessel growth)
What this could lead to: If successful, this combination could offer a new first-line treatment option for advanced uterine cancers, potentially shrinking tumors and delaying progression.
What could go wrong: The trial was terminated early, so results are limited. It was a small, phase 2 study, and the benefits seen may not hold up in larger trials. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma uterine corpus sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED ENDOMETRIAL CANCER SARCOMA OF UTERUS

Contacts and locations

Locations

Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, 110801, China
Linyi Cancer Hospital

Linyi, Shandong, 276002, China
Obstetrics & Gynecology Hospital of Fudan University

Shanghai, Shanghai Municipality, 200090, China
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Sun Yat-sen Memorial Hospital

Guangzhou, Guangdong, 510120, China
Taizhou People's Hospital

Taizhou, Jiangsu, 225399, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710061, China
TianJin Medical University Cancer Institute & Hopspital

Tianjin, Tianjin Municipality, 300181, China
Yantai Yuhuangding Hospital

Yantai, Shandong, 264099, China
Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430062, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.